VBLT Vascular Biogenics Ltd.

1.42
-0.01  -1%
Previous Close 1.43
Open 1.39
Price To Book 1.24
Market Cap 50,951,202
Shares 35,881,128
Volume 48,900
Short Ratio
Av. Daily Volume 87,239
Stock charts supplied by TradingView

NewsSee all news

  1. VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

    TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent

  2. VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented

  3. VBL Therapeutics Announces Third Quarter 2019 Financial Results

    TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update. "Our OVAL Phase 3

  4. VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

    Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE

  5. VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

    TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim data due 1Q 2020.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 top-line data released March 8, 2018 - primary endpoint not met.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis
Phase 2 trial to be initiated 4Q 2019.
VB-111
Colon cancer
Phase 2 trial to be initiated 4Q 2019.
VB-111
Recurrent glioblastoma multiforme (rGBM)

Latest News

  1. VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

    TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent

  2. VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented

  3. VBL Therapeutics Announces Third Quarter 2019 Financial Results

    TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update. "Our OVAL Phase 3

  4. VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

    Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE

  5. VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

    TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for